FDA
-
-
-
-
-
-
-
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
-
-
-
-
-
-
-
BioAtla (BCAB) Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma
-
-
-
-
-
-
-
BioAtla (BCAB) and Context Therapeutics (CNTX) Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362
-
-
-
-
-
-
-
BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024
-
-
-
-
-
-
-
BioAtla (BCAB) Announces FDA Clearance of IND Application for BA3361
-
-
-
-
-
-
-
BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress
-
-
-
-
-
-
-
BioAtla (BCAB) Provides Clinical Program Updates and Upcoming 2023 Milestones
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

